Celgene Corp (NASDAQ:CELG)

CAPS Rating: 4 out of 5

A biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases.

Recs

0
Player Avatar CellBlock9 (95.41) Submitted: 6/29/2010 9:45:40 PM : Outperform Start Price: $50.92 CELG Score: +8.19

S&P 5 star stock ; S&P500 2010 low on 6/29/2010

Featured Broker Partners


Advertisement